HCW Biologics (NASDAQ:HCWB) Trading Down 16%

HCW Biologics Inc. (NASDAQ:HCWB)’s stock price was down 16% on Thursday . The stock traded as low as $0.50 and last traded at $0.50. Approximately 43,125 shares traded hands during mid-day trading, an increase of 136% from the average daily volume of 18,261 shares. The stock had previously closed at $0.60.

HCW Biologics Trading Down 16.0 %

The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.10 and a current ratio of 0.10. The stock has a market cap of $19.05 million, a P/E ratio of -0.66 and a beta of 0.78. The stock has a 50-day moving average price of $0.56 and a 200-day moving average price of $1.02.

HCW Biologics (NASDAQ:HCWB) last announced its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%. The company had revenue of $0.62 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Avantax Planning Partners Inc. purchased a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 179,541 shares of the company’s stock, valued at approximately $220,000. Avantax Planning Partners Inc. owned about 0.50% of HCW Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.